Next Article in Journal
Quantification of Analgesic and Anti-Inflammatory Lipid Mediators in Long-Term Cryopreserved and Freeze-Dried Preserved Human Amniotic Membrane
Previous Article in Journal
EnsemDeepCADx: Empowering Colorectal Cancer Diagnosis with Mixed-Dataset Features and Ensemble Fusion CNNs on Evidence-Based CKHK-22 Dataset
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Rationally Improving Doramectin Production in Industrial Streptomyces avermitilis Strains

1
Key Laboratory of Synthetic Biology, The Center of Excellent Plant Molecular Sciences, The Chinese Academy of Sciences, Shanghai 200032, China
2
Institute of Biopharmaceuticals, Taizhou University, Taizhou 317000, China
*
Author to whom correspondence should be addressed.
Bioengineering 2023, 10(6), 739; https://doi.org/10.3390/bioengineering10060739
Submission received: 16 March 2023 / Revised: 3 June 2023 / Accepted: 13 June 2023 / Published: 20 June 2023
(This article belongs to the Section Biochemical Engineering)

Abstract

:
Avermectins (AVMs), a family of 16-membered macrocyclic macrolides produced by Streptomyces avermitilis, have been the most successful microbial natural antiparasitic agents in recent decades. Doramectin, an AVM derivative produced by S. avermitilis bkd mutants through cyclohexanecarboxylic acid (CHC) feeding, was commercialized as a veterinary antiparasitic drug by Pfizer Inc. Our previous results show that the production of avermectin and actinorhodin was affected by several other polyketide biosynthetic gene clusters in S. avermitilis and Streptomyces coelicolor, respectively. Thus, here, we propose a rational strategy to improve doramectin production via the termination of competing polyketide biosynthetic pathways combined with the overexpression of CoA ligase, providing precursors for polyketide biosynthesis. fadD17, an annotated putative cyclohex-1-ene-1-carboxylate:CoA ligase-encoding gene, was proven to be involved in the biosynthesis of doramectin. By sequentially removing three PKS (polyketide synthase) gene clusters and overexpressing FadD17 in the strain DM203, the resulting strain DM223 produced approximately 723 mg/L of doramectin in flasks, which was approximately 260% that of the original strain DM203 (approximately 280 mg/L). To summarize, our work demonstrates a novel viable approach to engineer doramectin overproducers, which might contribute to the reduction in the cost of this valuable compound in the future.

1. Introduction

Avermectins (AVMs) are a series of 16-membered macrocyclic lactones produced by Streptomyces avermitilis isolated from a soil sample collected in Shizuoka Prefecture, Japan, in 1978 (Figure 1A) [1]. AVMs and their derivatives were developed as the most successful antiparasitic compounds to prevent endo- and ectoparasitic infections of livestock and control important agricultural insects [2]. Because derivatives of avermectins (ivermectin) lowered the incidence of river blindness and other parasitic diseases, William C. Campbell and Satoshi Ōmura, the discoverers of avermectin, won the 2015 Nobel Prize in Physiology or Medicine together with the discovery of artemisinin [3,4]. Currently, avermectin and its derivative emamectin are the most popular natural pesticides worldwide [3].
Doramectin, which is sold commercially as Dectomax®, was produced by mutants of S. avermitilis lacking both branched-chain-2-oxo acid dehydrogenase (Bkd) and 5-O-methyltransferase (AveD) via feeding with cyclohexanecarboxylic acid (Figure 1A) [5,6]. Doramectin was already approved by the Food and Drug Administration (FDA) as a veterinary drug for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice, and mange mites in cattle, sheep, swine, and others [7]. It showed a longer plasma half-life and better persistent activity against the Ostertagia ostertagi and Cooperia oncophora infection of cattle [7,8].
Efforts to improve avermectin production have never stopped since the discovery of avermectin via classic mutagenesis and molecular genetic methods [9]. AVMs were proven to be synthesized through a type-I polyketide synthase (PKS) pathway. Since the sequencing of the complete gene cluster of avermectin by Ikeda, significant progress was achieved in studying biosynthetic and regulatory genes involved in avermectin biosynthesis [10]. The chromosome of S. avermitilis was predicted to harbor at least 37 secondary metabolic gene clusters (see the following website: http://avermitilis.ls.kitasato-u.ac.jp/ accessed on 13 November 2022). Among them, there are at least 13 polyketide biosynthetic gene clusters (BGCs), including those for avermectin. In addition to avermectin, oligomycin, filipin, THN (1,3,6,8-tetrahydroxynaphthalene), and an aromatic polyketide were reported to be produced by five polyketide biosynthetic pathways encoded in S. avermitilis [10]. A series of large-deletion mutants of S. avermitilis, which were constructed by removing nonessential genes and secondary metabolic biosynthetic gene clusters from the wild-type strain, were developed as superhosts for the heterologous production of secondary metabolites [11]. In many cases, the productivities of exogenous metabolites via the heterologous expression of the intact biosynthetic gene cluster in these S. avermitilis hosts were significantly improved compared with those of the original producing microorganisms [12]. After sequential deletions of 10 PKS and nonribosomal peptide synthetase biosynthetic gene clusters from Streptomyces coelicolor, the expression of the actinorhodin biosynthetic gene cluster in the mutant strain ZM12 resulted in approximately four times as much actinorhodin as its parent S. coelicolor strain M145 [13]. Many groups strived to improve doramectin production in recent decades via metabolic engineering or classical mutagenesis. However, the production of doramectin was still quite low; most strains could produce only approximately 1 g/L of doramectin either in flasks or at the bioreactor level [14,15,16]. The strain engineered by Wang could produce 50–60 mg/L of doramectin in flasks [15]. To date, the highest doramectin production was 1068 μg/mL in a 50 L fermenter [14].
Our group previously generated a doramectin overproducer via rational metabolic engineering of an industrial avermectin-producing strain (able to produce ca. 3 g/L avermectin B1a) by knocking out the bkd (branched-chain-2-oxo acid dehydrogenase-encoding gene) and aveD (5-O-methyltransferase-encoding gene) genes along with the replacement of the wild-type aveC (spiroketal formation and modification enzyme-encoding gene) with a synthetic aveC* mutant allele (a variant of the AveC-encoding gene with ten amino acid mutations) [17,18]. In addition, our previous works investigated the influence of the deletion of other PKS BGCs on avermectin production, showing that the termination of pks3, olm, and pte is most beneficial for avermectin overproduction [19]. Additionally, Meng et al. showed that the deletion of the type III polyketide synthase biosynthetic cluster rpp can be used to enhance the avermectin production of an industrial overproducer [20]. Because precursors such as malonyl-CoA and methyl-malonyl-CoA are the building blocks of PKS pathways, it is obvious that the competitive relationship among different coexpressed PKSs plays a key role in determining the production of specialized metabolites. All of these results suggest that the removal of competitive PKS gene clusters could direct the PKS biosynthetic flux to the target biosynthetic pathway, which would lead to the overproduction of target compounds.
Exogenous cyclohexanecarboxylic acid was added to be incorporated into the avermectin biosynthetic pathway to produce doramectin. In principle, CoA from precursors, not the free acid, can be efficiently loaded to the PKS assembly line to produce final products. In the doramectin biosynthetic pathway, we proposed that the appropriate CoA ligase would be responsible for the transformation of cyclohexanecarboxylic acid to cyclohexanecarboxylic CoA, which would then be involved in polyketide assembly lines. This process implied that cyclohexanecarboxylic acid activation was probably a key step in limiting doramectin production (Figure 1B).
Higher-production strains are imperative for industrial development and market expansion. In this paper, we discovered an endogenous CoA ligase (FadD17, encoded by SAV_3841) that was probably involved in the activation of cyclohexanecarboxylic acid. As we proposed, doramectin production in the industrial strain was increased significantly by the removal of the main competitive pks cluster and the overexpression of the endogenous CoA ligase involved in the cyclohexanecarboxylic acid activation.

2. Material and Methods

2.1. Bacterial Strains, Plasmids, and Cultivation Conditions

All bacterial strains and plasmids used in this study are listed in Table 1. Escherichia coli cells were grown at 37 °C in LB (lysogeny broth) (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl) or on agar supplied with the appropriate antibiotics. S. avermitilis strains were sporulated at 30 °C on ISP2 agar (International Streptomyces Project-2 medium containing 10 g/L malt extract, 4 g/L yeast extract, 4 g/L glucose, and 20 g/L agar; pH 7.2 adjusted with 2 N NaOH before autoclaving). MS medium (Mannitol Soya Flour, containing 20 g/L mannitol, 20 g/L soya flour, and 20 g/L agar, prepared with tap water and autoclaved twice with gentle shaking between the two runs) was used for intergeneric conjugation between E. coli ET12567 (pUZ8002) and S. avermitilis. For fermentation to produce doramectin, S. avermitilis strains were incubated on an orbital shaker (shaker type: Forma Thermo Scientific 481 orbital shaker; orbital size: 2.5 cm; manufactured by Thermo Electron Inc., Marietta, OH, USA) at 200 rpm at 28 °C in seed (20 g/L corn starch, 10 g/L defatted soybean flour, 5 g/L glucose, 10 g/L cotton seed flour, pH 7.2) and fermentation (100 g/L corn starch liquefied with thermostable α-amylase, 20 g/L defatted soybean flour, 10 g/L cotton seed flour, 5 g/L yeast extract, NaCl 1 g/L, 2 g/L K2HPO4, 1 g/L MgSO4, 0.8 g/L CHC, 7 g/L CaCO3, pH 7.0) medium as described by Xia [18].

2.2. DNA Cloning and Sequence Analysis

Alkaline lysis prep of plasmid DNA, transformation of the E. coli host, and PCR amplification were performed according to procedures from Sambrook et al. [24]. The protocols for genomic and plasmid DNA isolation and genetic manipulation in Streptomyces were described by Kieser et al. [25]. The sequences of oligonucleotide primers for PCR verification and vector construction are described in Table 2. High-fidelity DNA polymerase (FastPfu, TransGen Biotech Inc., Beijing, China) was used for PCRs in ABI9700 Thermocyclers according to the instructions provided by the manufacturer (Thermo Fisher Scientific Inc., Waltham, MA, USA). The reaction programs were initial denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 94 °C for 45 s, annealing at 58 °C for 45 s, and extension at 72 °C for 30–120 s (the extension time depended on the length of the target fragments, approximately 2 kb/min). A final extension step was performed at 72 °C for 10 min. The reaction conditions for amplification of the resistance cassette for lambda Red recombination were described in Gust’s reports [21].

2.3. Vector Construction and Genetic Manipulation

For the sequential deletion of the biosynthetic gene clusters, first, the genes were replaced by the FRT-aac(3)IV-FRT cassette (plasmid pHY773 containing this cassette is presented in Figure S1A of the Supplementary Materials). Then, the recombined cosmids were digested with the proper restriction enzyme and cloned into pHY-642 (Figure S1B of the Supplementary Materials). Then, the deletion vectors were constructed via cleavage of the aac(3)IV gene by the FLP recombinase (the schematic strategy to delete the target cluster is illustrated in Figures S2A and S4A of the Supplementary Materials). The vector for deletion of the olm gene cluster was constructed by cloning the flanking fragments into pHY-642 (Figure S3A of the Supplementary Materials). All vectors were introduced into S. avermitilis via conjugation. The positive recombinants were verified via PCR amplification and Sanger DNA sequencing (Shanghai Sangon Bioengineering Inc., Shanghai, China).

2.4. Analysis of Doramectin Production with High-Performance Liquid Chromatography (HPLC)

Thirteen-day fermentation cultures were extracted with 9 volumes of methanol, followed by centrifugation at 16,000× g for 10 min. The liquid phase was passed through a 0.2 μm membrane filter and analyzed with an Agilent 1260 HPLC system (Agilent Inc., Santa Clara, CA, USA) using an Agilent Poroshell 120 Ec-C18 column (2.7 μm, 4.6 × 50 mm). The column was eluted at a flow rate of 1 mL/min for 10 min with acetonitrile:methanol:H2O (40:40:20). Metabolites were monitored at a wavelength of 245 nm. The production was calibrated with standard doramectin from Sigma-Aldrich Inc. (Indianapolis, IN, USA).

2.5. Statistical Methods

One-way ANOVA was employed to compare the production of different mutant strains. GraphPad Prism version 9.0.0 for Windows (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. The significance of the differences between strains were evaluated using a t test.

3. Results

3.1. Sequential Deletion of the PKS Clusters from the Doramectin-Producing Strain

On the basis of our previous doramectin single component-producing strain DM203, the recombinant strains DM205, DM206, and DM209 were obtained via sequential deletion of the pks3, olm, and pte biosynthetic gene clusters, respectively. The details of the deletion regions are shown in Table 3. All recombinants were verified via PCR amplification with the primers listed in Table 2 and Sanger sequencing of the amplified fragments (Figures S2B, S3B and S4B of the Supplementary Materials). The production of doramectin in these recombinants was investigated via flask fermentation. The production of these strains is presented in Figure 2.
With the deletion of more gene clusters, the doramectin production gradually increased. Strain DM209 (with the deletion of the pks3, olm, and pte clusters) demonstrated the highest production among the tested strains. The doramectin production of DM209 was approximately 60% higher than that of the initial strain DM203.

3.2. Verification of the CHC Activation Protein-Encoding Gene

A search of the annotation database of the S. avermitilis genome revealed 23 putative CoA ligase-encoding genes (Table S1) (the search was carried out at http://avermitilis.ls.kitasato-u.ac.jp/ accessed on 13 November 2022). Among them, FadD17 (SAV_3841) was annotated as cyclohex-1-ene-1-carboxylate:CoA ligase, implying that FadD17 is probably involved in the activation of CHC, the precursor of doramectin biosynthesis. Therefore, the FadD17 overexpression vector pSETD17 was constructed via cloning downstream of the constitutively strong promoter PermE*. The plasmid was incorporated into DM206 to construct the FadD17 overexpression strain DM207. Strain DM215 was constructed as a fadD17 null mutant derived from strain DM206 with PCR-targeting methods (the schematic strategy to delete the target cluster is illustrated in Figure S5 of the Supplementary Materials). The doramectin production of strains DM206, DM207, and DM215 is compared in Figure 3.
The overexpression of FadD17 can enhance the production of doramectin. The deletion of fadD17 led to a significant decrease in the doramectin production. The doramectin production of strain DM215 was approximately 20% of that in the DM206 strain. This result implies that FadD17 is probably the key CoA ligase involved in the CHC activation for doramectin biosynthesis in S. avermitilis.

3.3. Construction of a Doramectin Hyperproduction Strain

The above results show that both the deletion of the PKS cluster and the overexpression of FadD17 (SAV_3841) could promote doramectin production. Therefore, the FadD17 overexpression vector was introduced into the DM209 strain (the strain with the deletion of three PKS clusters). The doramectin production of the resulting recombinant strain DM223 was compared with that of the DM203 and DM209 strains (Figure 4).
The doramectin production of DM223 was approximately 723 mg/L, which was approximately 260% higher than that of the initial strain DM203.

4. Discussion

The pedigree of the constructed S. avermitilis mutant strains, which are derivatives of DM203, is presented in Figure 5. The deletion of the pks-3, olm, and pte biosynthetic gene clusters significantly enhanced the doramectin synthesis in S. avermitilis (Figure 2). In fact, we also tried to delete more PKS clusters based on strain DM209. However, all the obtained strains showed no significant enhancement in the production of doramectin. Moreover, some strains showed deficiencies in growth. The S. coelicolor strain ZM12, which was obtained via sequential deletions of 10 PKS and nonribosomal peptide synthetase biosynthetic gene clusters in the M145 strain, can produce approximately four times as much actinorhodin as its parent [13]. However, some intermediate strains, such as ZM8 and ZM6, produced less actinorhodin than the parent strain M145. We hypothesized that the deletion of the precursor competition pathway would be helpful in redirecting the secondary metabolic flux. However, the flux directions could be case dependent. The manipulation of the competitive PKS gene cluster can be a potentially effective approach in improving the production of target compounds.
For mutasynthesis, feeding precursor activation plays an important role in determining the production of the final products. In this paper, we show that the proper CoA ligase is involved in the biosynthesis of doramectin. By combining the deletion of competitive gene clusters and the overexpression of precursor activation genes, the production of doramectin was significantly increased in the final strains. All of these results show that cluster deletion and precursor activation was a rational approach for doramectin industrial strain improvements.
Usually, CHC is fed only once during doramectin fermentation in flasks. Higher CHC concentrations in the broth cause growth defects [14,15]. The optimization of the CHC feeding process is probably an option to enhance the production of doramectin. A cyclohexylcarbonyl CoA biosynthetic gene cluster was reported to be engineered to construct a doramectin strain [9,14,26]. Endogenous cyclohexylcarbonyl CoA can probably help solve this dilemma [15,26]. The initial S. avermitilis strain can produce approximately 3 g/L of avermectin B1a, which means that the total AVM production could probably be up to 5 g/L. Therefore, much can be done to promote doramectin production. With the development of synthetic biology, the coordination of the biosynthesis of doramectin and CHC-CoA probably facilitates their production.
With the development of synthetic biology in recent years, gene editing technologies such as CRISPR–Cas have begun to be widely applied to engineer Streptomyces [27,28,29]. Nevertheless, there are obstacles in engineering industrial strains for low genetic manipulation efficiency. Here, the long flanking arms from the cosmid can facilitate homologous recombination for engineering industrial S. avermitilis strains. For targeting deletion regions, CRISPRi approaches could be an efficient way to test target regions [28,29,30].

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/bioengineering10060739/s1, Figure S1: physical maps of plasmids pHY773 and pHY-642; Figure S2: markerless deletion of the pks-3 cluster from S. avermitilis DM203; Figure S3: schematic strategy for markerless deletion of the olm cluster from S. avermitilis DM205; Figure S4: markerless deletion of a partial pte cluster from S. avermitilis DM206; Figure S5: disruption of fadD17 from S. avermitilis DM205; Table S1: putative CoA ligase-encoding genes in S. avermitilis.

Author Contributions

H.X. and Z.Q. designed this research. F.D. and Q.X. carried out all the experiments. H.X. and F.D. analyzed the data. H.X. and F.D. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National High Technology Research and Development Program of China (2012AA022107) and the Scientific Research Foundation of Taizhou (No. 2001xg07). And The APC was funded by the Natural Science Foundation of Zhejiang Province (LY19C010002).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article or Supplementary Materials.

Acknowledgments

We are grateful to Keith Chater for kindly providing the plasmids and strains used in PCR-targeting system. The assistance of the colleagues of Institute of Biopharmaceuticals during preparing manuscript is gratefully acknowledged.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Burg, R.W.; Miller, B.M.; Baker, E.E.; Birnbaum, J.; Currie, S.A.; Hartman, R.; Kong, Y.L.; Monaghan, R.L.; Olson, G.; Putter, I.; et al. Avermectins, new family of potent anthelmintic agents: Producing organism and fermentation. Antimicrob. Agents Chemother. 1979, 15, 361–367. [Google Scholar] [CrossRef] [Green Version]
  2. Thuan, N.H.; Pandey, R.P.; Sohng, J.K. Recent advances in biochemistry and biotechnological synthesis of avermectins and their derivatives. Appl. Microbiol. Biotechnol. 2014, 98, 7747–7759. [Google Scholar] [CrossRef]
  3. Chen, J.; Liu, M.; Zhang, L. Avermectin, from winning the Nobel Prize to “innovation in China”. Wei Sheng Wu Xue Bao 2016, 56, 543–558. [Google Scholar]
  4. Ikeda, H. Natural products discovery from micro-organisms in the post-genome era. Biosci. Biotechnol. Biochem. 2017, 81, 13–22. [Google Scholar] [CrossRef] [Green Version]
  5. Denoya, C.D.; Fedechko, R.W.; Hafner, E.W.; McArthur, H.A.; Morgenstern, M.R.; Skinner, D.D.; Stutzman-Engwall, K.; Wax, R.G.; Wernau, W.C. A second branched-chain alpha-keto acid dehydrogenase gene cluster (bkdFGH) from Streptomyces avermitilis: Its relationship to avermectin biosynthesis and the construction of a bkdF mutant suitable for the production of novel antiparasitic avermectins. J. Bacteriol. 1995, 177, 3504–3511. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Dutton, C.J.; Gibson, S.P.; Goudie, A.C.; Holdom, K.S.; Pacey, M.S.; Ruddock, J.C.; Bu’Lock, J.D.; Richards, M.K. Novel avermectins produced by mutational biosynthesis. J. Antibiot. 1991, 44, 357–365. [Google Scholar] [CrossRef] [Green Version]
  7. Stutzman-Engwall, K.; Conlon, S.; Fedechko, R.; Kaczmarek, F.; McArthur, H.; Krebber, A.; Chen, Y.; Minshull, J.; Raillard, S.; Gustafsson, C. Engineering the aveC gene to enhance the ratio of doramectin to its CHC-B2 analogue produced in Streptomyces avermitilis. Biotechnol. Bioeng. 2003, 82, 359–369. [Google Scholar] [CrossRef] [PubMed]
  8. Stutzman-Engwall, K.; Conlon, S.; Fedechko, R.; McArthur, H.; Pekrun, K.; Chen, Y.; Jenne, S.; La, C.; Trinh, N.; Kim, S.; et al. Semi-synthetic DNA shuffling of aveC leads to improved industrial scale production of doramectin by Streptomyces avermitilis. Metab. Eng. 2005, 7, 27–37. [Google Scholar] [CrossRef]
  9. Wang, W.; Li, S.; Li, Z.; Zhang, J.; Fan, K.; Tan, G.; Ai, G.; Lam, S.M.; Shui, G.; Yang, Z.; et al. Harnessing the intracellular triacylglycerols for titer improvement of polyketides in Streptomyces. Nat. Biotechnol. 2020, 38, 76–83. [Google Scholar] [CrossRef]
  10. Ikeda, H.; Kazuo, S.Y.; Omura, S. Genome mining of the Streptomyces avermitilis genome and development of genome-minimized hosts for heterologous expression of biosynthetic gene clusters. J. Ind. Microbiol. Biotechnol. 2014, 41, 233–250. [Google Scholar] [CrossRef] [PubMed]
  11. Komatsu, M.; Uchiyama, T.; Omura, S.; Cane, D.E.; Ikeda, H. Genome-minimized Streptomyces host for the heterologous expression of secondary metabolism. Proc. Natl. Acad. Sci. USA 2010, 107, 2646–2651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Komatsu, M.; Komatsu, K.; Koiwai, H.; Yamada, Y.; Kozone, I.; Izumikawa, M.; Hashimoto, J.; Takagi, M.; Omura, S.; Shin-ya, K.; et al. Engineered Streptomyces avermitilis host for heterologous expression of biosynthetic gene cluster for secondary metabolites. ACS Synth. Biol. 2013, 2, 384–396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Zhou, M.; Jing, X.; Xie, P.; Chen, W.; Wang, T.; Xia, H.; Qin, Z. Sequential deletion of all the polyketide synthase and nonribosomal peptide synthetase biosynthetic gene clusters and a 900-kb subtelomeric sequence of the linear chromosome of Streptomyces coelicolor. FEMS Microbiol. Lett. 2012, 333, 169–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Pan, X.; Cai, J. Improved fermentation yield of doramectin from Streptomyces avermitilis N72 by strain selection and glucose supplementation strategies. Fermentation 2023, 9, 121. [Google Scholar] [CrossRef]
  15. Wang, J.; Pan, H.; Tang, G. Production of doramectin by rational engineering of the avermectin biosynthetic pathway. Bioorg. Med. Chem. Lett. 2011, 21, 3320–3323. [Google Scholar] [CrossRef] [PubMed]
  16. Zhao, X.; Wang, Y.; Wang, S.; Chen, Z.; Wen, Y.; Song, Y. Construction of a doramectin producer mutant from an avermectin-overproducing industrial strain of Streptomyces avermitilis. Can. J. Microbiol. 2009, 55, 1355–1363. [Google Scholar] [CrossRef] [PubMed]
  17. Lu, Z.; Dang, F.; Xia, H.; Qin, Z. Increasing doramectin content of industrial strain by introduction of a synthetic multiple-mutated aveC* gene. Chin. J. Antibiot. 2014, 39, 574–578. [Google Scholar] [CrossRef]
  18. Xia, H.; Huang, J.; Hu, M.; Shen, M.; Xie, P.; Zhang, L.; Wang, H.; Qin, Z. Construction of an ordered cosmid library of Streptomyces avermitilis for genetic modification of the industrial strains. Chin. J. Antibiot. 2009, 34, 340–343. [Google Scholar]
  19. Hu, M.; Xia, H.; Qin, Z. Effects on productivity of avermectin by knockout of 10 polyketide biosynthetic gene clusters in Streptomyces avermitilis genome. Microbiol. China 2014, 41, 1471–1476. [Google Scholar] [CrossRef]
  20. Meng, L.; Xiong, Z.; Chu, J.; Wang, Y. Enhanced production of avermectin by deletion of type III polyketide synthases biosynthetic cluster rpp in Streptomyces avermitilis. Lett. Appl. Microbiol. 2016, 63, 384–390. [Google Scholar] [CrossRef]
  21. Gust, B.; Challis, G.L.; Fowler, K.; Kieser, T.; Chater, K. PCR-targeted Streptomyces gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin. Proc. Natl. Acad. Sci. USA 2003, 100, 1541–1546. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Bierman, M.; Logan, R.; O’Brien, K.; Seno, E.; Rao, R.; Schoner, B. Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene 1992, 116, 43–49. [Google Scholar] [CrossRef] [PubMed]
  23. Dang, F.; Xia, H.; Qin, Z. Construction of the industrial strains for nemadectin production with less byproducts by genetically engineering. Chin. J. Antibiot. 2014, 39, 579–583. [Google Scholar] [CrossRef]
  24. Sambrook, J.; Fritsch, E.; Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 1989. [Google Scholar]
  25. Kieser, T.; Bibb, M.; Buttner, M.; Chater, K.; Hopwood, D. Practical Streptomyces Genetics; The John Innes Foundation: Norwich, UK, 2000. [Google Scholar]
  26. Cropp, T.; Wilson, D.; Reynolds, K. Identification of a cyclohexylcarbonyl CoA biosynthetic gene cluster and application in the production of doramectin. Nat. Biotechnol. 2000, 18, 980–983. [Google Scholar] [CrossRef]
  27. Tan, L.L.; Heng, E.; Zulkarnain, N.; Hsiao, W.C.; Wong, F.T.; Zhang, M.M. CRISPR/Cas-mediated genome editing of Streptomyces. Methods Mol. Biol. 2022, 2479, 207–225. [Google Scholar] [CrossRef]
  28. Zhao, Y.; Li, L.; Zheng, G.; Jiang, W.; Deng, Z.; Wang, Z.; Lu, Y. CRISPR/dCas9-mediated multiplex gene repression in Streptomyces. Biotechnol. J. 2018, 13, e1800121. [Google Scholar] [CrossRef]
  29. Li, L.; Wei, K.; Zheng, G.; Liu, X.; Chen, S.; Jiang, W.; Lu, Y. CRISPR-Cpf1-assisted multiplex genome editing and transcriptional repression in Streptomyces. Appl. Environ. Microbiol. 2018, 84, e00827-18. [Google Scholar] [CrossRef] [Green Version]
  30. Tian, J.; Yang, G.; Gu, Y.; Sun, X.; Lu, Y.; Jiang, W. Developing an endogenous quorum-sensing based CRISPRi circuit for autonomous and tunable dynamic regulation of multiple targets in Streptomyces. Nucleic Acids Res. 2020, 48, 8188–8202. [Google Scholar] [CrossRef]
Figure 1. Schematic graph of the strategy to enhance doramectin production in S. avermitilis. (A) The chemical structures of avermectin B1a and doramectin. The different moieties are shown in red. (B) The proposed schematic strategy to improve doramectin production in S. avermitilis.
Figure 1. Schematic graph of the strategy to enhance doramectin production in S. avermitilis. (A) The chemical structures of avermectin B1a and doramectin. The different moieties are shown in red. (B) The proposed schematic strategy to improve doramectin production in S. avermitilis.
Bioengineering 10 00739 g001
Figure 2. The production of doramectin in the three pks null mutant strains. Strains DM205 (∆pks-3), DM206 (∆pks3-∆olm), and DM209 (∆pks3-∆olm-∆pte) are all derived from DM203. Two asterisks denote a statistically significant difference (p ≤ 0.01) between the production of two strains.
Figure 2. The production of doramectin in the three pks null mutant strains. Strains DM205 (∆pks-3), DM206 (∆pks3-∆olm), and DM209 (∆pks3-∆olm-∆pte) are all derived from DM203. Two asterisks denote a statistically significant difference (p ≤ 0.01) between the production of two strains.
Bioengineering 10 00739 g002
Figure 3. The effect on the production of doramectin by FadD17 compared to the parent strain DM205. DM207 is equivalent to DM205 with a PermE*-driven fadD17. DM215 is a fadD17 mull mutant derived from DM205. Two asterisks denote a statistically significant difference (p ≤ 0.01) between the production of two strains.
Figure 3. The effect on the production of doramectin by FadD17 compared to the parent strain DM205. DM207 is equivalent to DM205 with a PermE*-driven fadD17. DM215 is a fadD17 mull mutant derived from DM205. Two asterisks denote a statistically significant difference (p ≤ 0.01) between the production of two strains.
Bioengineering 10 00739 g003
Figure 4. The production of the doramectin hyperproduction strain DM223. Two asterisks denote a statistically significant difference (p ≤ 0.01) between the production of two strains.
Figure 4. The production of the doramectin hyperproduction strain DM223. Two asterisks denote a statistically significant difference (p ≤ 0.01) between the production of two strains.
Bioengineering 10 00739 g004
Figure 5. Pedigree of the mutant S. avermitilis strains. Steps involved in sequentially deleting the three endogenous secondary metabolite gene clusters.
Figure 5. Pedigree of the mutant S. avermitilis strains. Steps involved in sequentially deleting the three endogenous secondary metabolite gene clusters.
Bioengineering 10 00739 g005
Table 1. Plasmids and strains used in this study.
Table 1. Plasmids and strains used in this study.
Strain or PlasmidsGenotype/DescriptionSources/Reference
Streptomyces avermitilis
DM203Doramectin-producing strain[17]
DM205pks3 mutant of DM203This study
DM206pks3-olm mutant of DM205This study
DM209pks3-olm-∆pte mutant of DM206This study
DM207DM205 with a copy of PermE*-fadD17This study
DM215fadD17 mutant of DM205This study
DM223DM209 with a copy of PermE*-fadD17This study
Escherichia coli
DH5αHost for general cloningInvitrogen
BW25113 (pIJ790)Host containing L-arabinose-inducible lambda Red recombination system[21]
BT340Host containing inducible FLP recombination system[21]
ET12567 (pUZ8002)dam dcm hsdM cm kan, containing a nontransmissible RP4-derived plasmid pUZ8002[22]
Plasmids
pIJ773bla colE1-ori FRT-aac(3)IV-oriT-FRT cassette[21]
pHY773bla colE1-ori FRT-aac(3)IV-FRT cassette[23]
pHY642Bla colE1-oritsr oriT[23]
pSET152colE1 ori aac(3)IV oriT phiC31int attP lacZα[22]
pCSA4-65Cosmid contains a c. 40-kb insert (includes the pks3 gene cluster) of S. avermitilis[19]
pCSA11-69Cosmid contains a c. 40-kb insert (includes the pteA1 gene) of S. avermitilis[19]
pCSA4-93Cosmid contains a c. 40-kb insert (includes the fadD17 gene) of S. avermitilis[19]
pCSA4-65Apks3 gene cluster deletion of pCSA4-65 (PCR-targeting)This study
pCSA11-69Apte gene cluster deletion of pCSA11-69 (PCR-targeting)This study
pSPD11pks3 gene cluster markerless deletion plasmidThis study
pSPD17olm gene cluster markerless deletion plasmidThis study
pSPD25pte gene cluster markerless deletion plasmidThis study
pSETD17pSET152 derivative for PermE*-driven expression of fadD17This study
pCSA4-93AfadD17 gene deletion of pCSA4-93 (PCR-targeting)This study
Table 2. Primers used in this study.
Table 2. Primers used in this study.
PrimerSequences (5′-3′)Used for
pks3FGCAGATCTTGCGCAGGGAGACGAACGCGTCGGGCCCGGCTGTAGGCTGGAGCTGCTTCAmplification of the FRT-aac(3)IV-FRT cassette to target the pks3 cluster in pCSA4-65 via lambda Red recombination
pks3RAGGCCCCGGCCGCGGCGCCCTTGGGCCGTCAGCGGGGTGATTCCGGGGATCCGTCGACC
pks3DFGACCACCTTCACCTCGTTGCTo verify the deletion and replacement of pks3 in S. avermitilis DM205 and pCSA4-65A, respectively.
pks3DRCATCAGCCTTTCCGACTTCC
olmLFCGGAAGCTTTCCTCGAGGGACTCACCGACAmplification of the upstream and downstream homologous arms to construct pSPD17.
olmLRGAGGGATCCTGAGAGCGCCTCCAGTTCCC
olmRFTGCGGATCCCCATAGAACCTTTCGTGCTA
olmRRTACGAATTCAACTCGGCGTCCATGTGGAT
olmDFATGACGGGAAGGGCGGAGGTGTTo verify the deletion of the olm cluster in S. avermitilis DM206
olmDRGTCGTAGAGGAGGAAGAGCGGTGC
pteFCGACGAACGTGGTCACGCCCAGCTCGTGCAGGGTGTGCAATTCCGGGGATCCGTCGACCAmplification of the FRT-aac(3)IV-FRT cassette to target the pte cluster in pCSA11-69 via lambda Red recombination
pteRGCCCACACCCGCGTCGCCAGAAACTCCCGCACCTGCGCCTGTAGGCTGGAGCTGCTTC
pteDFAGGGATGCGTCCTGAGTGAGATo verify the deletion and replacement of pte in S. avermitilis DM209 and pCSA11-69A, respectively
pteDRCGGTGAACATTGCGACTGCTT
fadD17FGGAATTCCATATGGTGAACGACACCGCACACGCGCTCAConstruction of pSETD17 and pHX85D17
fadD17RGGAATTCCATATG TCACCGCGCATAGCGCTCCCTCAGC
fadD17-59FGCGCTCAGCACCTCCGGCACGCTCTGGGAACTCGTCGTCATTCCGGGGATCCGTCGACCAmplification of the FRT-aac(3)IV-oriT-FRT cassette to target fadD17 in pCSA4-93 via lambda Red recombination
fadD17-58RGATCCTCGATCTCCTTCGCCGAGATGTTCTCGCCCTTGCTGTAGGCTGGAGCTGCTTC
fadD17-PFCTGGATACCAGCAGGCTAGTGCCTo verify the deletion and replacement of pks-3 in S. avermitilis DM207 and pCSA4-93A, respectively
fadD17-PRCGCCCGCAGATACGAGGTCAT
Table 3. Information on the deleted gene clusters from S. avermitilis DM203.
Table 3. Information on the deleted gene clusters from S. avermitilis DM203.
Deleted ClustersAnnotated Region *Deletion Region *Length of Deletion Region (bp)
Start (nt)End (nt)Start (nt)End (nt)
pks32,773,8782,784,8412,777,9202,784,8386918
olm3,534,5253,634,5923,534,5293,634,591100,062
pte487,415567,017546,803568,02721,224
* The nt positions refer to the genome sequence of the S. avermitilis strain MA-4680, accession No. NC_003155. The pks3 was deleted in strain DM205. The pks3 and olm were deleted in strain DM206. The pks3, olm, and pte were deleted in strain DM209.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dang, F.; Xu, Q.; Qin, Z.; Xia, H. Rationally Improving Doramectin Production in Industrial Streptomyces avermitilis Strains. Bioengineering 2023, 10, 739. https://doi.org/10.3390/bioengineering10060739

AMA Style

Dang F, Xu Q, Qin Z, Xia H. Rationally Improving Doramectin Production in Industrial Streptomyces avermitilis Strains. Bioengineering. 2023; 10(6):739. https://doi.org/10.3390/bioengineering10060739

Chicago/Turabian Style

Dang, Fujun, Qingyu Xu, Zhongjun Qin, and Haiyang Xia. 2023. "Rationally Improving Doramectin Production in Industrial Streptomyces avermitilis Strains" Bioengineering 10, no. 6: 739. https://doi.org/10.3390/bioengineering10060739

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop